VERAPOINT
LIVE

Serial Number

98600337

Owner

LUSIS BIOSCIENCES, INC.

Attorney

Steven K. Lee

Filing Date

Jun 13, 2024

Add to watchlist:

No watchlists yet
View on USPTO

VERAPOINT Trademark

Serial Number: 98600337

VERAPOINT is a trademark filed by LUSIS BIOSCIENCES, INC. on June 13, 2024. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently pending registration.

Owner Contact Info

LUSIS BIOSCIENCES, INC. (14 trademarks)

3500 BREAKWATER COURT
HAYWARD, CA 94545

Entity Type: 03

Sansureus, Inc. (14 trademarks)

1900 Proforma Ave.
Ontario, CA 91761

Entity Type: 03

Trademark Details

Filing Date

June 13, 2024

Registration Date

Not Registered

Published for Opposition

November 5, 2024

Goods & Services

Injectable pharmaceuticals for treatment of anaphylactic reactions; Chemical reagents for medical purposes; Antibiotic tablets; Allergy tablets; Medicated water for the treatment of illnesses attributed to insufficient cellular energy; Medicated water for the treatment of allergies, cough, cold, flu, headache, pain; Medicated water for the treatment of infectious diseases, skin diseases and conditions, and internal diseases and conditions; Medicated water for the treatment of pain, nausea and muscle spasms; Medicated water-based solutions for treating skin infections and skin conditions; Medicated water for the treatment of gastrointestinal disorders; Antibiotic ointments; Anti-inflammatory ointments; Medicated ointments for treating dermatological conditions; Purified biochemical medical diagnostic reagents, namely, protein arrays, enzymes, and fluorescent dyes; Biochemical drugs for the treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system, inflammatory disorders, dermatological conditions, oncological diseases, blood diseases, connective tissue disorders, ophthalmic diseases, and gastroenterological disorders; Diagnostic preparations for medical purposes; Chemico-pharmaceutical preparations in the nature of biological indicators, in-vivo diagnostic agents, in-vitro diagnostic reagents for the diagnosis, monitoring, treatment and prevention of cancer, inflammatory disorders, oncological disorders, infectious diseases, and diseases related to the immune system and respiratory system; Chemical preparations in the nature of biological indicators, in-vivo diagnostic agents, in-vitro diagnostic reagents for the diagnosis, monitoring, treatment and prevention of cancer, inflammatory disorders, oncological disorders, infectious diseases, and diseases related to the immune system and respiratory systems; Chemical preparations in the nature of biological indicators, in-vivo diagnostic agents, in-vitro diagnostic reagents for the diagnosis, monitoring, treatment and prevention of cancer, inflammatory disorders, oncological disorders, infectious diseases, and diseases related to the immune system and respiratory system; Chemical reagents for medical or veterinary purposes

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 17, 2025 EXRA
SOU EXTENSION 2 GRANTED
Dec 16, 2025 EX2G
SOU EXTENSION 2 FILED
Dec 16, 2025 EXT2
SOU TEAS EXTENSION RECEIVED
Dec 16, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 18, 2025 EXRA
SOU EXTENSION 1 GRANTED
Jun 18, 2025 EX1G
SOU EXTENSION 1 FILED
Jun 17, 2025 EXT1
SOU TEAS EXTENSION RECEIVED
Jun 17, 2025 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Dec 17, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 5, 2024 NPUB
PUBLISHED FOR OPPOSITION
Nov 5, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Oct 16, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 28, 2024 CNSA
ASSIGNED TO EXAMINER
Sep 27, 2024 DOCK
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Sep 11, 2024 ASGN
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 13, 2024 NWOS
NEW APPLICATION ENTERED
Jun 13, 2024 NWAP